<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62244">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02131636</url>
  </required_header>
  <id_info>
    <org_study_id>199201-004</org_study_id>
    <nct_id>NCT02131636</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of AGN-199201 once daily compared to
      vehicle for the treatment of persistent moderate to severe facial erythema associated with
      rosacea.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Participants with at Least a 2-Grade Decrease from Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point Scales</measure>
    <time_frame>Baseline, Day 29</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with at Least a 2-Grade Decrease from Baseline on SSA Using a 5-Point Scale</measure>
    <time_frame>Baseline, Day 29</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA)</measure>
    <time_frame>Baseline, Day 29</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction Assessment for Rosacea Facial Redness Using a 5-Point Scale</measure>
    <time_frame>Day 29</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Assessment for Rosacea Facial Redness (Skin Sensation Domain Score) Using a 5-Point Scale</measure>
    <time_frame>Day 29</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with at Least a 1-Grade Decrease from Baseline on SSA Using a 5-Point Scale</measure>
    <time_frame>Baseline, Day 1- hour 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Erythema</condition>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>AGN-199201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-199201 applied to the face once daily for 29 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle to AGN-199201 applied to the face once daily for 29 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-199201</intervention_name>
    <description>AGN-199201 applied to the face once daily for 29 days.</description>
    <arm_group_label>AGN-199201</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle to AGN-199201</intervention_name>
    <description>Vehicle to AGN-199201 applied to the face once daily for 29 days.</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Moderate to severe persistent facial erythema associated with rosacea.

        Exclusion Criteria:

          -  Greater than 3 inflammatory lesions on the face

          -  Current treatment with monoamine oxidase (MAO) inhibitors

          -  Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, scleroderma or
             Sjogren's syndrome.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allergan Inc.</last_name>
    <email>clinicaltrials@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com</url>
    <description>More Information</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>May 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosacea</mesh_term>
    <mesh_term>Erythema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
